Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-1 receptor accessory protein (IL1RAP) short hairpin RNA is an experimental RNA interference (RNAi) therapeutic designed to silence the expression of the IL1RAP gene. IL1RAP is a co-receptor for the interleukin-1 receptor and is highly expressed on the surface of leukemic stem cells in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). By reducing IL1RAP levels, this shRNA inhibits downstream inflammatory signaling and disrupts the amplification of FLT3 and c-KIT pathways, which are critical for the survival and proliferation of leukemic stem cells. Research conducted at the Albert Einstein College of Medicine has demonstrated that targeting IL1RAP with shRNA induces cell death in AML cells while sparing normal hematopoietic stem cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-1 receptor accessory protein short hairpin RNA.